000 | 02006 a2200601 4500 | ||
---|---|---|---|
005 | 20250513131504.0 | ||
264 | 0 | _c19971112 | |
008 | 199711s 0 0 eng d | ||
022 | _a0006-4971 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHarousseau, J L | |
245 | 0 | 0 |
_aComparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). _h[electronic resource] |
260 |
_bBlood _cOct 1997 |
||
300 |
_a2978-86 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAcute Disease |
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xtherapeutic use |
650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xtherapeutic use |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aBone Marrow Transplantation |
650 | 0 | 4 |
_aCytarabine _xtherapeutic use |
650 | 0 | 4 |
_aDaunorubicin _xanalogs & derivatives |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIdarubicin _xtherapeutic use |
650 | 0 | 4 |
_aLeukemia, Myeloid _xdrug therapy |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMultivariate Analysis |
650 | 0 | 4 | _aOutcome Assessment, Health Care |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRemission Induction |
700 | 1 | _aCahn, J Y | |
700 | 1 | _aPignon, B | |
700 | 1 | _aWitz, F | |
700 | 1 | _aMilpied, N | |
700 | 1 | _aDelain, M | |
700 | 1 | _aLioure, B | |
700 | 1 | _aLamy, T | |
700 | 1 | _aDesablens, B | |
700 | 1 | _aGuilhot, F | |
700 | 1 | _aCaillot, D | |
700 | 1 | _aAbgrall, J F | |
700 | 1 | _aFrancois, S | |
700 | 1 | _aBriere, J | |
700 | 1 | _aGuyotat, D | |
700 | 1 | _aCasassus, P | |
700 | 1 | _aAudhuy, B | |
700 | 1 | _aTellier, Z | |
700 | 1 | _aHurteloup, P | |
700 | 1 | _aHerve, P | |
773 | 0 |
_tBlood _gvol. 90 _gno. 8 _gp. 2978-86 |
|
999 |
_c9346441 _d9346441 |